Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK
Stilnoct 5 mg film-coated Tablets.
| Pharmaceutical Form |
|---|
|
Coated tablets for oral administration. |
Round white film-coated tablets containing 5 mg zolpidem tartrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Zolpidem |
Zolpidem is an imidazopyridine which preferentially binds the omega-1 receptor subtype (also known as the benzodiazepine-1 subtype) which corresponds to GABA-A receptors containing the alpha-1 sub-unit, whereas benzodiazepines non-selectively bind both omega-1 and omega-2 subtypes. The modulation of the chloride anion channel via this receptor leads to the specific sedative effects demonstrated by zolpidem. These effects are reversed by the benzodiazepine antagonist flumazenil. |
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Film coating: Hypromellose |
Cartons of 4, 14, 28 or 56 tablets in PVC/foil blister strips of 7 or 14 tablets.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK
Trading as:
Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PTUK
PL 04425/0618
03 December 2009
| Drug | Countries | |
|---|---|---|
| STILNOCT | Finland, Ireland, Netherlands, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
